Effective cancer therapy remains an important unmet medical challenge. For instance, while treatment of oestrogen receptor-positive (ER^+^) breast cancer patients with tamoxifen reduces disease recurrence by 50% at 5 years, patient mortality is only reduced by 28%. Moreover, ER-negative (ER^−^) breast cancer patients have earlier disease recurrence and reduced survival times compared with ER^+^ breast cancer patients. Therefore, there is still a need to identify novel targets for therapeutic intervention that can provide better treatment options. A novel mediator that has an important role in cancer is the bioactive lipid, sphingosine 1-phosphate (S1P; [@bib10]). Sphingosine 1-phosphate is formed by the phosphorylation of sphingosine to S1P, catalysed by two isoforms of sphingosine kinase (SK), termed SK1 and SK2. Sphingosine 1-phosphate is cleaved by S1P lyase to produce palmitaldehyde and phosphoethanolamine ([@bib10]). Sphingosine 1-phosphate can also be dephosphorylated by S1P phosphatase to recycle into sphingolipids ([@bib10]). Sphingosine 1-phosphate is an agonist of sphingosine 1-phosphate (S1P)-specific G-protein-coupled receptors, termed S1P~1-5~ ([@bib10]) and also binds to intracellular protein targets ([@bib2]) to promote cell responses, such as growth, migration and survival. Intracellular S1P can also be released from cancer cells and has the potential to bind to S1P receptors to promote cell growth/survival in an autocrine/paracrine manner. This process is called 'inside-out\' signalling ([@bib12]).

A role for S1P in cancer is evident from studies demonstrating increased expression of SK1 in many different tumour types including breast cancer. Indeed, high tumour expression of SK1 in ER^+^ breast cancer is correlated with poor patient survival rates and earlier disease recurrence on tamoxifen ([@bib7] and [@bib15]). Sphingosine kinase 1 expression is also higher in ER^--^ compared with ER^+^ breast tumours. Indeed, these patients have a poor prognosis compared with the ER^+^ tumour group ([@bib11]). High expression of SK1 in astrocytoma is also associated with the poor prognosis of patients with Grade 4 tumours ([@bib14]). Taken together, this evidence strongly supports the notion that SK1 is a 'sensor\' for promoting cancer growth and survival. Indeed, cancer cells overexpressing SK1 form larger vascularised-resistant tumours compared with tumours lacking ectopically expressed SK1 ([@bib10]). Sphingosine 1-phosphate receptors are also involved in cancer progression. For instance, S1P binding to S1P~1~ stimulates the migration of fibrosarcoma cells ([@bib4]), whereas binding to S1P~3~ promotes gastric cancer cells migration ([@bib16]). Furthermore, high S1P~1~ and S1P~3~ expression in ER^+^ breast cancer patients is correlated with poor prognosis ([@bib15]).

The human epidermal growth factor receptor 2 (HER2)/*neu*/*c-erbB-2* gene encodes a 185-kDa transmembrane receptor tyrosine kinase. In all, 30% of primary breast cancers contain overexpressed HER2/*neu* and this is correlated with poor prognosis and therapeutic resistance ([@bib3]). We have reported that HER2/ErbB2 functionally interacts with sphingosine 1-phosphate receptor 4 (S1P~4~) in ER^−^ MDA-MB-453 breast cancer cells. Sphingosine 1-phosphate binding to S1P~4~ stimulates activation of ERK-1/2 and this is contingent on HER2 ([@bib8]). The functional interaction of the S1P~4~ receptor with an oncogene provides evidence that S1P~4~ might have an important role in ER^−^ breast cancer progression. We have therefore analysed tumours from ER^−^ breast cancer patients with respect to the clinical prognostic significance of S1P~4~ and SK1 in these tumours.

Material and methods
====================

Materials
---------

All general biochemicals were from Sigma-Aldrich (Poole, UK). High-glucose Dulbecco\'s modified Eagle\'s medium (DMEM) and European foetal calf serum and penicillin--streptomycin were from Invitrogen (Paisley, UK). Suppliers of antibodies were as follows: anti-phosphorylated ERK-1/2 antibody, Santa Cruz (Santa Cruz, CA, USA); Anti-ERK2 antibody, BD Transduction Laboratories (Oxford, UK); Anti-HER2 antibody, New England Biolabs UK Ltd (Hitchin, UK); Anti-SK1 antibody, Abgent (Abingdon, UK) and kind gift from Dr A Huwiler (University of Berne, Bern, Switzerland); Anti-S1P~4~ antibody, Exalpha (Shirley, MA, USA); anti-*α*-actin antibody and conjugated anti-IgG secondary antibodies, Sigma (Gillingham, Dorset, UK). Sphingosine 1-phosphate was from Avanti Polar Lipids (Alabaster, AL, USA). SKi (2-(*p*-hydroxyanilino)-4-(*p*-chlorophenyl)thiazole) was from Merck Biosciences (Nottingham, UK).

Patients
--------

All patients (*n*=140) were diagnosed with operable invasive breast carcinoma between 1995 and 1998 in the Greater Glasgow area. These patients received standard adjuvant treatment according to protocols at the time of diagnosis. The patient follow-up details included information on clinical attendances, recurrence and metastasis, date and cause of death as well as adjuvant therapy details. Ethics approval was granted by the Local Ethics Committee.

Tissue microarray (TMA) construction
------------------------------------

Tissue microarrays were already available for use in this study. The 0.6-mm^2^ cores of breast cancer tissue, identified by the pathologist (EM), were removed from representative areas of the tumour taken from breast cancer patients at the time of surgical resection. All TMA blocks were constructed in triplicate.

Immunohistochemistry
--------------------

Staining for ER, progesterone receptor (PR), ki67 proliferation index and HER2 had been previously performed for the cohort. The ER and PR protein expression was scored using the weighted histoscore technique. Tumours were classified as ER and PR positive if they had a weighted histoscore of \>10. All tumours were classified as ER^−^ and five tumours as PR positive. Ki67 was scored by counting positive and negative nuclei in the tumour specimen and then the percentage of positive cells was calculated to provide a proliferation index. Tumours were classified as having low, moderate or high proliferation index as calculated by tertiles, with 22 tumours being classified as highly proliferative. Human epidermal growth factor receptor 2 expression was scored by the NICE approved scoring system for the HercepTest: 0=no membrane staining; 1+=faint, partial membrane staining; 2+=weak, complete membrane staining in \>10% of invasive cancer cells and 3+=intense, complete membrane staining in \>10% of invasive cancer cells. A score of 3+ is regarded as positive, 2+ is equivocal and referred for FISH testing and 0 and 1+ are negative ([@bib5]). A total of 39 tumours were classified as HER2 positive.

The TMA slides were first dewaxed and rehydrated through a series of xylene and alcohol washes. Antigen retrieval for SK1 was performed by microwaving the slides under pressure in a citrate buffer for 5 min (pH 6.0) and for S1P~4~ in 10 mM citrate buffer at 96 °C for 20 min. Endogenous peroxidase was blocked using 3% hydrogen peroxide for 20 min and non-specific background staining was reduced for SK1 by blocking with casein for 20 min and for S1P~4~ by blocking with 1 : 20 horse serum for 30 min. The sections were then incubated with the primary antibody (1 : 50 SK1, and 1 : 100 S1P~4~) at 25 °C in a humidified incubator for 60 min (SK1) and 4 °C overnight (S1P~4~). EnVision-HRP conjugate (DAKO, Cambridgeshire, UK) was used for signal amplification, and positive staining was identified using 3,3′-diaminobenzidine chromagen (Vector Laboratories, Peterborough, UK). The slides were then counterstained with haematoxylin and Scott\'s Tap Water Substitute before dehydration and mounting.

Scoring
-------

The protein expression of each core (three per tumour specimen) was assessed using the weighted histoscore method (H score method). The weighted histoscore grades staining intensity as negative (0), weak (1), moderate (2) and strong (3) and then multiplies the percentage of tumour cells within each category. The histoscore range is from 0 (minimum) to 300 (maximum). Agreement between observers was calculated using interclass correlation coefficient.

Statistical analysis
--------------------

Disease-specific survival rates were generated using the Kaplan--Meier method. The log-rank test was used to compare significant differences between subgroups using univariate analysis. On the basis of the results of the univariate analysis a multivariate analysis was then carried out. The multivariate stepwise Cox-regression analysis was performed to identify factors that were independently associated with disease-specific death. A stepwise backward procedure was used to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding *P*-value had to be \>0.05.

Inter-relationships between clinical parameters, PR, HER2, SK1, S1P~4~ and Ki67 status were calculated using the *χ*^2^ test. Data are expressed as median and range. The statistical analyses were performed using a statistical software package (SPSS 15.0 Inc., Chicago, IL, USA).

Cell culture
------------

MDA-MB-453 breast cancer cells were obtained from the ATCC (Rockville, MD, USA) and grown in a monolayer culture in high-glucose DMEM with 10% European Fetal Calf Serum (EFCS) and 1% pen--strep (penicillin G sodium 10^4^ units ml^−1^--streptomycin sulphate 10 mg ml^−1^) at 37 °C with 5% CO~2~. Cells were serum starved for 48 h before stimulation with S1P.

Western blotting
----------------

Analysis of proteins by SDS--PAGE and western blotting was performed as described previously by us ([@bib1]) using anti-phosphorylated ERK-1/2, anti-*α*-actin, anti-SK1 and anti-ERK2 antibodies.

Immunofluorescence microscopy
-----------------------------

Cells were plated onto autoclaved 13-mm glass coverslips and grown to 60% confluence before serum starvation for 48 h before stimulation. Cells were fixed with 3.7% formaldehyde in phosphate-buffered saline (PBS) for 10 min, permeabilised with 0.1% Triton X-100 in PBS for 1 min before incubation in blocking solution (5% EFCS and 1% bovine serum albumin in PBS) for 30 min at room temperature. Coverslips were then incubated with anti-HER2 antibody (1 : 100 dilution in blocking solution) overnight at 4 °C. Coverslips were washed with PBS and incubated with FITC-conjugated anti-rabbit IgG secondary antibody (1 : 100 dilution in blocking solution), as appropriate, at room temperature for 1 h. Coverslips were washed in PBS, excess moisture was removed with tissue and mounted on glass slides using Vectashield (Vector Laboratories) hard set mounting medium with DAPI. Immunofluorescence was visualised using a Nikon (Surrey, UK) E600 epifluorescence microscope.

Results
=======

Clinicopathological details
---------------------------

The cohort consisted of 140 breast cancer patients with ER^−^ tumours. The median age was 55 years (IQR 45--64). In all, 94% of the cancer specimens were pathologically categorised as Grade 2 and 3, and the median size of the invasive cancer was 22 mm (IQR 15--30 mm). About 50% of the patients were axillary lymph node positive. At last follow-up, 41 patients had died of their disease, 18 of intercurrent disease while 75 patients were alive. The latter group had a mean patient follow-up of 13.1 years (minimum follow-up was 11.8 years and the maximum follow-up was 14.75 years). During the follow-up period, 47 patients experienced recurrence with a mean time of 4.9 years (minimum time to recurrence 0.5 years and maximum time to recurrence 8.5 years). The association with clinical parameters, recurrence (disease-free survival) and disease-specific survival are provided in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, respectively, and correlations between the clinicopathological characteristics of this cohort are shown in [Table 3](#tbl3){ref-type="table"}.

*Sphingosine kinase 1 expression in ER^−^ breast cancer*
--------------------------------------------------------

Sphingosine kinase 1 expression was successfully assessed in all tumours analysed. A typical IHC using anti-SK1 antibody is shown in [Figure 1](#fig1){ref-type="fig"}. Antibody specificity for SK1 in IHC has previously been confirmed by us ([@bib7]; [@bib15]). Tumours were subdivided into those with high or low SK1 expression using the method described by [@bib11]. Therefore, low SK1 membrane expression was below 88 histoscore units (128 patients), low SK1 cytoplasmic expression was below 82 histoscore units (116 patients) and low SK1 nuclear expression was below 75 histoscore units (110 patients). *χ*^2^ analysis demonstrated that the membrane and cytoplasmic SK1 expression correlated with age. However, no correlations were observed between any other clinicopathological parameters or S1P~4~ levels ([Table 3](#tbl3){ref-type="table"}). Sphingosine kinase 1 expression at any cellular location was not associated with disease-free survival ([Table 1](#tbl1){ref-type="table"}) or disease-specific survival on univariate analysis ([Table 2](#tbl2){ref-type="table"}). However, high SK1 expression in the HER2^+^ tumours was significantly associated with shorter disease-specific survival (*P*=0.0001) compared with HER2^+^ patients with low SK1 expression in their tumours. Those patients with HER2-positive tumours and high SK1 expression have a mean disease-free survival of 2.9 years and a mean disease-specific survival time of 4.1 years compared with 6.45 years for disease-free survival and 12 years for disease-specific survival in the low tumour SK1 expression group. These results should be interpreted with some caution because of low patient numbers.

*Sphingosine 1-phosphate expression in ER^−^ breast cancer*
-----------------------------------------------------------

A typical IHC using anti-S1P~4~ antibody is shown in [Figure 1](#fig1){ref-type="fig"}. Antibody specificity for S1P~4~ has been previously confirmed by us ([@bib8]). Sphingosine 1-phosphate receptor 4 expression was successfully assessed in all tumours analysed. Tumours were subdivided into those with high or low S1P~4~ expression using the method described by [@bib11]. Therefore, low S1P~4~ membrane expression was below 83 histoscore units (114 patients), low S1P~4~ cytoplasmic expression was below 82 histoscore units (120 patients) and low S1P~4~ nuclear expression was below 84 histoscore units (118 patients). *χ*^2^ analysis demonstrated that S1P~4~ expression was not correlated with clinicopathological parameters. However, the membrane, cytoplasmic and nuclear S1P~4~ expression levels correlated with each other ([Table 3](#tbl3){ref-type="table"}). High cytoplasmic tumour S1P~4~ (which might represent post-activated internalised receptor) expression in patients was associated with shorter disease-free survival (*P*=0.014. [Table 1](#tbl1){ref-type="table"}, [Figure 2A](#fig2){ref-type="fig"}) and disease-specific survival (*P*=0.004, [Table 2](#tbl2){ref-type="table"}, [Figure 2B](#fig2){ref-type="fig"}) compared with patients with low cytoplasmic tumour S1P~4~ expression on univariate analysis. Those patients with tumours that had high S1P~4~ expression have a mean disease-free survival of 5.2 years and a mean disease-specific survival time of 8 years compared with the low tumour S1P~4~ expression group, the latter having a disease-free survival time of 6.65 years and a mean disease-specific survival time of 11.7 years. When entered into multivariate analysis both disease-free survival and disease-specific survival were demonstrated to be independent of other significant clinicopathological parameters ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}).

Sphingosine 1-phosphate receptor 4 tumour expression was not associated with any one clinical subtype. However, high SK1 expression in tumours that also exhibited a low level of S1P~4~ expression was significantly associated with shorter disease-free survival and disease-specific survival (*P*=0.043 and *P*=0.033, respectively) compared with patients with low SK1 and low S1P~4~ tumour expression ([Figures 3A and B](#fig3){ref-type="fig"}). In addition, there was a significant association of shorter disease-specific survival in patients with tumours that express high SK1 or S1P~4~ (29 patients) compared with those that express low SK1 and S1P~4~ levels (108 patients; *P*=0.001; [Figure 3C](#fig3){ref-type="fig"}). Thus, patients whose tumours contain low levels of both SK1 and S1P~4~ have a mean disease-specific survival of 11.9 years compared with 7.95 years in patients with tumours that contain high SK1 or S1P~4~ expression ([Figure 3C](#fig3){ref-type="fig"}). This was independent of nodal status on multivariate analysis (*P*=0.016, hazard ratio of 2.3 (95% CI 1.2--4.412).

*Functional interaction between S1P~4~, SK1 and HER2*
-----------------------------------------------------

We have previously demonstrated that the S1P-induced activation of ERK-1/2 in MDA-MB-453 cells involves S1P~4~ and HER2 ([@bib8]). Thus, S1P stimulation of the ERK-1/2 pathway was reduced by siRNA knockdown of S1P~4~ or HER2, and by pharmacological inhibitors, including the S1P~2/4~ antagonist, JTE-013 and ErbB2 inhibitor II ([@bib8]). Our finding that high SK1 expression in tumours that also contain low levels of S1P~4~ exhibit significantly shorter disease-free survival and disease-specific survival compared with patients with low SK1 and S1P~4~ tumour expression suggests that a functional interaction between SK1 and S1P~4~ might operate in ER^−^ breast cancer. To test this possibility *in vitro*, we assessed the effect of SK1 inhibitors on S1P~4~-mediated signalling in ER^−^ MDA-MB-453 cells. For this purpose, we used the SK1 inhibitors, SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole)), which is a inhibitor of SK1 activity ([@bib9]; [@bib13]; [@bib6]). We demonstrate here that the chronic treatment (24 h) of MDA-MB-453 cells with SKi promoted the loss of SK1 (Mr∼42 kDa) expression from these cells ([Figure 4](#fig4){ref-type="fig"}) consistent with our previous findings that SKi induces the ubiquitin-proteasomal degradation of SK1 in cancer cells ([@bib9]; [@bib13]; [@bib6]). SKi also induced a substantial reduction in S1P-stimulated activation of ERK-1/2 ([Figure 5](#fig5){ref-type="fig"}), thereby providing evidence for the existence of a functional S1P~4~/SK1 regulatory pathway regulating ERK-1/2 in these cells. As HER2 is essential for S1P stimulation of ERK-1/2 ([@bib8]), the current data also define a functional interaction between SK1 and HER2. In addition, we have previously shown that basal ERK-1/2 activation is dependent on HER2 tyrosine kinase activity and is independent of S1P~4~ ([@bib8]). It is therefore noteworthy that the treatment of MDA-MB-453 cells with SKi reduced basal ERK-1/2 activation ([Figure 4](#fig4){ref-type="fig"}). We have also found that acute treatment (15 min) of MDA-MB-453 cells with SKi altered HER2 trafficking in MDA-MB-453 cells ([Figure 5](#fig5){ref-type="fig"}). Immunofluorescence staining of unstimulated MDA-MB-453 cells with anti-HER2 antibody demonstrates that HER2 is localised in punctuate bodies at the plasma membrane/cell periphery ([Figure 5](#fig5){ref-type="fig"}). Treatment of these cells with SKi causes a marked redistribution of HER2, which localised into cytoplasmic punctuate bodies and accumulated into an unidentified intracellular compartment ([Figure 5](#fig5){ref-type="fig"}). In contrast, the treatment of these cells with S1P induced the re-localisation of HER2 (in punctuate bodies) from the plasma membrane to the cytoplasm, with little if any accumulation into the intracellular compartment ([Figure 5](#fig5){ref-type="fig"}).

Discussion
==========

The major finding of this study is that S1P~4~ is linked with poor prognosis in ER^−^ breast cancer patients as evidenced by shorter disease-free survival and disease-specific survival of patients who have high S1P~4~ expression in their tumours compared with those that have low receptor expression. These findings are significant because S1P~4~ has a restricted tissue distribution, being localised largely to immune cells. The receptor is therefore a possible target for drug intervention because of the potential to limit side effects. More importantly, we have previously demonstrated a functional coupling of S1P~4~ with HER2, suggesting that combined treatment of cells with S1P~4~ antagonists and ErbB2 inhibitors might represent a more effective treatment regime for ER^−^ breast cancer patients compared with ErbB2 inhibitors alone.

We also demonstrate here that while SK1 expression was not associated with disease-free survival or disease-specific survival in aggressive tumours when considered alone, high SK1 expression was associated with shorter disease-free and disease-specific survival in patients whose tumour contained low levels of S1P~4~. These findings demonstrate that SK1 might become more important when combined with S1P~4~, suggesting a functional link between these two proteins that is defined by their expression levels. Further evidence to support this functional interaction was obtained by the demonstration that the SK1 inhibitor, SKi, reduced SK1 expression and decreased the S1P/S1P~4~-induced stimulation of ERK-1/2 in MDA-MB-453 cells. There are several possibilities for how SK1 and S1P~4~ might interact functionally. For instance, 'inside-out\' signalling involves activation of SK1 and the subsequent release of S1P from cells, which might then act on S1P~4~ receptors on the cancer cell. Alternatively, S1P binding to S1P~4~ might induce activation of SK1, and the resulting S1P formed might function to activate intracellular proteins to promote cancer cell growth/survival. Therefore, stimulation of S1P~4~ at low expression might be increased by S1P formed from highly expressed SK1 (e.g., inside-out signalling). Alternatively, signalling from S1P~4~ might be amplified by downstream activation of highly expressed SK1 in the tumours. Moreover, we have previously demonstrated that exogenous S1P (via S1P~3~) induces the translocation of SK1 from the cytoplasm to the plasma membrane of ER^+^ MCF-7 cells, and that siRNA knockdown of SK1 in these cells reduces the activation of ERK-1/2 by exogenous S1P ([@bib7]).

We have also reported here that high SK1 expression in the ER^−^/HER2^+^ tumours is significantly associated with shorter disease-specific survival compared with HER2^+^ patients with low SK1 expression in their tumours. A functional interaction between HER2 and SK1 in MDA-MB-453 cells is evidenced by the demonstration that pharmacological inhibition of SK1 activity results in altered HER2 trafficking in MDA-MB-453 cells. The interaction of SK1 and HER2 suggests that their cooperation enhances ER^−^ cancer progression. This contrasts with the functional interaction between SK1 and HER2 in ER^+^ breast cancer patients ([@bib7]). In this regard, we have demonstrated that HER2 increases SK1 expression in ER^+^/HER2^+^ breast cancer cells ([@bib7]). This leads to a negative feedback loop in which SK1 induces a reduction in HER2 expression and ablates S1P-stimulated migration; the latter due to an SK1-induced deactivation/degradation of p21 activated protein kinase 1, which is normally required for motility. Moreover, we have shown that high SK1 expression in the ER^+^/HER2^+^ breast cancer tumours is correlated with increased patient survival and reduced disease recurrence on Tamoxifen ([@bib7]), thereby demonstrating a protective role for SK1 in this tumour phenotype ([@bib7]).

Taken together, these findings highlight the different effect of S1P signalling signatures in ER^+^ and ER^−^ breast cancers on clinical prognosis, influenced by S1P receptor subtypes, SK1 and HER2. The findings in this study also highlight the need to define the role of S1P receptor subtypes, SK1 and HER2 in shaping the precise cancer disease phenotype in order to inform on the best therapeutic approach. Our findings suggest that both S1P~4~ and SK1 represent novel biomarkers predictive of prognostic significance in ER^−^ breast cancer. Indeed, the S1P~4~-SK1 regulatory module might represent an important target for drug intervention designed to prevent ER^−^ breast cancer progression.
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![ An example of SK1 and S1P~4~ expression detected in ER^−^ breast cancer samples with anti-SK1 or anti-S1P~4~ antibody, respectively.](bjc201298f1){#fig1}

![ (**A**) High cytoplasmic S1P~4~ expression is associated with shorter disease-free survival. (**B**) High cytoplasmic S1P~4~ expression is associated with shorter disease-specific survival.](bjc201298f2){#fig2}

![ (**A**) High cytoplasmic SK1 expression in a low S1P~4~ expression background is associated with shorter disease-free survival compared with patients with low tumour S1P~4~ and SK1 expression. (**B**) High cytoplasmic SK1 expression in a low S1P~4~ expression background is associated with shorter disease-specific survival compared with patients with low tumour S1P~4~ and SK1 expression. (**C**) High SK1 or S1P~4~ expression is associated with shorter disease-specific survival compared with patients with low SK1 and S1P~4~ expression in their tumours.](bjc201298f3){#fig3}

![ The effect of SKi on the ERK-1/2 pathway in MDA-MB-453 cells. MDA-MB-453 cells were treated with SKi (10 *μ*ℳ) for 24 h before stimulation with and without S1P (10 *μ*ℳ, 10 min). Western blots showing the effect of SKi on SK1 expression and the basal and S1P-induced activation of ERK-1/2 activation. Phosphorylated ERK-1/2 was detected with anti-phospho ERK-1/2 antibody and SK1 was detected with anti-SK1 antibody. ERK2 and *α*-actin was also detected to ensure comparable protein loading. Results are representative of three independent experiments.](bjc201298f4){#fig4}

![ The effect of SKi on HER2 trafficking in MDA-MB-453 cells. MDA-MB-453 cells were treated with SKi (10 *μ*ℳ) for 15 min before stimulation with and without S1P (5 *μ*ℳ, 10 min). The images are immunofluorescence stains with anti-HER2 antibody showing the effect of SKi and/or S1P on the subcellular localisation of HER2. Results are representative of two experiments. The arrows in the control panel (C) indicate localisation of HER2 to the punctuate bodies at the plasma membrane, while in Ski- and S1P/Ski-treated cells they identify the localisation of HER2 to an intracellular compartment and small punctuate intracellular bodies. In the S1P panel, arrows identify HER2 localisation to small punctuate intracellular bodies.](bjc201298f5){#fig5}

######  The patient cohort\'s characteristics correlated with disease-free survival

                                                         **Univariate**   **Multivariate**              
  ----------------------------------------- ------------ ---------------- ------------------ ----- ----------
  Age (\<50 year/\>50 year)                    48/92     0.639                                          
  Tumour type (duct/lob/tub/others)           129/2/9    0.190                                          
  Grade (unknown/G1/G2/G3)                   4/4/25/107  0.492                                          
  Size (mm; unknown/\<20, 20--50, \>50)      4/64/69/2   \<0.001          NS                            
  Lymph node (unknown/positive/negative)      1/70/67    0.020            0.045              2.1    1.1--4.2
  HER2 status (unknown/positive/negative)     1/100/39   0.497                                          
                                                                                                        
  Ki67 (unknown/low/ moderate/high)          2/73/43/22  0.088                                          
                                                                                                        
  SK1 membrane (positive/negative)             128/12    0.121                                          
  SK1 cytoplasmic (positive/negative)          116/24    0.276                                          
  SK1 nuclear (positive/negative)              110/30    0.595                                          
  S1P~4~ membrane (positive/negative)          114/26    0.557                                          
  S1P~4~ cytoplasmic (positive/negative)       120/20    0.014            0.026              2.4    1.1--5.2
  S1P~4~ nuclear (positive/negative)           118/22    0.214                                          

Abbreviations: HER2=human epidermal growth factor receptor 2; HR=hazard ratio; IQR=interquartile range; NS=non significant; S1P~4~=sphingosine 1-phosphate receptor 4; SK1=sphingosine kinase 1.

Each clinical and pathological parameter was correlated to recurrence (*P*-values). Grade=Bloom and Richardson grade; Histology: duct=ductal carcinoma; lob=lobular carcinoma; tub=tubular carcinoma; others including mucinous, mucoid and micropapillary carcinoma. Univariate analysis is performed for each parameter. However, only markers with a *P*-value of \<0.05 are included in the multivariate model.

######  The patient cohort\'s characteristics correlated to disease-specific survival

                                                        **Univariate**   **Multivariate**               
  ---------------------------------------- ------------ ---------------- ------------------ ------ ----------
  Age (\<50 year/\>50 year)                   48/92     0.941                                           
  Tumour type (duct/lob/tub/others)          129/2/9    0.142                                           
  Grade (unkown/G1/G2/G3)                   4/4/25/107  0.444                                           
  Size (mm; unkown/\<20, 20--50, \>50)      4/64/69/2   0.088                                           
  Lymph node (unkown/positive/negative)      1/70/67    0.001            0.002              3.0     1.5--6.0
  HER2 status (unkown/positive/negative)     1/100/39   0.806                                           
                                                                                                        
  Ki67 (unknown/low/ moderate/high)         2/73/43/22  0.109                                           
                                                                                                        
  SK1 membrane (positive/negative)            128/12    0.118                                           
  SK1 cytoplasmic (positive/negative)         116/24    0.559                                           
  SK1 nuclear (positive/negative)             110/30    0.563                                           
  S1P~4~ membrane (positive/negative)         114/26    0.539                                           
  S1P~4~ cytoplasmic (positive/negative)      120/20    0.004            0.031              2.27    1.1--4.5
  S1P~4~ nuclear (positive/negative)          118/22    0.392                                           

Abbreviations: HER2=human epidermal growth factor receptor 2; HR=hazard ratio; IQR=interquartile range; S1P~4~=sphingosine 1-phosphate receptor 4 ; SK1=sphingosine kinase 1.

Each clinical and pathological parameter was correlated to disease-specific survival (*P*-values). Grade=Bloom and Richardson grade; Histology: duct=ductal carcinoma; lob=lobular carcinoma; tub=tubular carcinoma; others including mucinous, mucoid and micropapillary carcinoma. Univariate analysis is performed for each parameter. However, only markers with a *P*-value of \<0.05 are included in the multivariate model.

######  Correlations between SK1 and S1P~4~, expression and the clinicopathological characteristics of the cohort

  **Variables**                             **Tumour type**   **Grade**   **Size**   **LN status**   **HER status**   **Ki67 status**   **SK1 mem**  **SK1 cyto**   **SK1 nuc**    **S1P** ~**4**~**mem**   **S1P** ~**4**~**cyto**   **S1P** ~**4**~**nuc**
  ---------------------------------------- ----------------- ----------- ---------- --------------- ---------------- ----------------- ------------- -------------- ------------- ------------------------ ------------------------- ------------------------
  Age (\<50 year/\>50 year)                       NS             NS          NS           NS               NS               NS              NS       0.025          0.029                    NS                       NS                        NS
  Tumour type (duct/lob/tub/others)                            \<0.001       NS           NS               NS               NS              NS       NS             NS                       NS                       NS                        NS
  Grade (G1/G2/G3)                                                         0.024         0.001             NS              0.05             NS       NS             NS                       NS                       NS                        NS
  Size (mm; \<20, 20--50, \>50)                                                          0.013             NS               NS              NS       NS             NS                       NS                       NS                        NS
  Lymph node (positive/negative)                                                                           NS               NS              NS       NS             NS                       NS                       NS                        NS
  HER2 status (positive/negative)                                                                                          0.037            NS       NS             NS                       NS                       NS                        NS
  Ki67 status (low/moderate/high)                                                                                                           NS       NS             NS                       NS                       NS                        NS
                                                                                                                                                                                                                                                 
  SK1 membrane (positive/negative)                                                                                                                   NS             NS                       NS                       NS                        NS
  SK1 cytoplasmic (positive/negative)                                                                                                                               NS                       NS                       NS                        NS
  SK1 nuclear (positive/negative)                                                                                                                                                            NS                       NS                        NS
  S1P~4~ membrane (positive/negative)                                                                                                                                                                               \<0.001                  \<0.001
  S1P~4~ cytoplasmic (positive/negative)                                                                                                                                                                                                      0.011

Abbreviations: cyto=cytoplasmic; HER2=human epidermal growth factor receptor 2; HR=hazard ratio; IQR=interquartile range; mem=membrane; nuc=nuclei; NS=non significant; IL=lymph node; S1P~4~=sphingosine 1-phosphate receptor 4; SK1=sphingosine kinase 1.

Tumour type: duct=ductal carcinoma; lob=lobular carcinoma; tub=tubular carcinoma; others including mucinous, mucoid and micropapillary carcinoma; Grade: Bloom and Richardson grade. *χ*^2^ test: NS *P*-values.
